Relationship of p53 molecular abnormalities with flow cytometry and growth factor receptor content in lung cancer

Clinica Chimica Acta

Volumn 269, Issue 1, 1998, Pages 63-76

  Lopez Guerrero J A ^a   Bolufer Gilabert, P ^a   Marugan De La Concha I ^a   Barragan Gonzalez E ^a   Vera Sempere, F J ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

EGFR; Epidermal growth factor receptor; Flow cytometry; LOH; Loss of heterozygosity; Lung cancer; P53; p53 Western blot; Single strand conformation polymorphisms; SSCP

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; EXON; FLOW CYTOMETRY; GENE MAPPING; GROWTH RATE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEFECT; RADIOASSAY; RECEPTOR DENSITY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR GROWTH;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; FLOW CYTOMETRY; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0345627988     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)00186-1     Document Type: Article

References (35)

1. Birrer MJ, Minna JD Molecular genetics of lung cancer. Semin Oncol. 15:1988;226-235.
2. Schmidt RA, Rusch VW, Piantadosi S A flow cytometric study of non-small cell lung cancer classified as T1N0. Cancer. 69:1992;78-85.
3. Kern JA, Schwartz DA, Nordberg JEet al. p185neu expression in human lung adenocarcinomas predicts survival. Cancer Res. 50:1990;5184-5191.
4. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJA, Rodenhuis S Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 83:1991;1024-1027.
5. Isobe H, Miyamoto H, Shimizu Tet al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer. 65:1990;1391-1395.
6. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
7. Levine AJ, Perry ME, Chang Aet al. The 1993 Walter Hubert Lecture: the role of p53 tumor-suppressor gene in tumorigenesis. Br J Cancer. 69:1994;409-416.
8. Kandioler D, Mueller MR, Mannhalter CH Carcinogen-specific mutations in p53 tumor suppressor gene in lung cancer. J Thorac Cardiovasc Surg. 107:1994;1095-1098.
9. Harris CC, Hollstein M Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 329:1993;1318-1327.
10. Takeshima Y, Seyama T, Bennett WPet al. P53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet. 342:1993;1520-1521.
11. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M P53 mutation hotspot in radon-associated lung cancer. Lancet. 343:1994;86-87.
12. Bodner SM, Minna JD, Jensen SMet al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 7:1992;743-749.
13. Mitsudomi T, Steinberg SM, Nau MMet al. P53 gene mutation in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 7:1992;171-180.
14. Ridanpää M, Karjalainen A, Anttila S, Vainio H, Husgafvel-Pursiainen K Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. Int J Oncol. 5:1994;1109-1117.
15. Volm M, Efferth T, Mattern J Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinoma of the lung. Clinical and biological correlations. Anticancer Res. 12:1992;11-20.
16. Papadakis E, Malliri A, Linardopoulos S, Karaiossifidi H, Field JK, Spandidos DA Ras and p53 expression in non-small cell lung cancer patients: p53 over-expression correlates with poor prognosis. Int J Oncol. 1:1992;403-413.
17. Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res. 83:1992;101-106.
18. Pezzella F, Turkley H, Kuzu Y, Gatter KC, Mason DY, Harris DY Reversible p53 expression in lung cancer. Lancet. 340:1992;992.
19. Heyderman E, Dagg B P53 immunostaining in benign breast disease. Lancet. 338:1991;1532.
20. Rivas CI, Wisniekski D, Strife Aet al. Constitutive expression of P53 protein in enriched normal human marrow blast cell populations. Blood. 79:1992;1982-1986.
21. Schmidt RA, Rusch VW, Piantadosi S A flow cytometric study of non-small cell lung cancer classified as T1N0. Cancer. 69:1992;78-85.
22. Cerny T, Barnes DM, Hasleton Pet al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumors. Br J Cancer. 54:1986;265-269.
23. Veale D, Aschroft T, Marsh C, Gibson GJ, Harris AL Epidermal growth factor receptors in non-small cell lung cancers. Br J Cancer. 55:1987;513-516.
24. Dazzi H, Hasleton PS, Thatcher Net al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue correlation of EGF-R with histology, tumor size, node status and survival. Br J Cancer. 59:1989;746-749.
25. Dittadi R, Gion M, Brazzale Aet al. Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer. 64:1991;741-744.
26. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet. i:1987;1398-1402.
27. Bradford MM A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem. 72:1976;248-254.
28. Bolufer P, Miralles F, Rodriguez Aet al. Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics. Eur J Cancer. 26:1990;283-290.
29. Maniatis T, Fritsch E, Sambrook J. Molecular cloning. A laboratory manual. New York: Cold Spring Harbor Laboratory, 1982.
30. Castresana JS, Rubio MP, Vazquez JJet al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer. 55:1993;562-565.
31. Orita M, Suzuki Y, Sekiya T, Hayashi K Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
32. Meltzer SJ, Yin J, Huang Yet al. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by polymerase chain reaction. Proc Natl Acad Sci USA. 88:1991;4976-4980.
33. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 14:1993;1085-1089.
34. Dosaka-Akita H, Shindoh M, Fujino Met al. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol. 102:1994;660-664.
35. Chakravarty G, Redkar A, Mittra I A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer. 74:1996;1181-1187.